New drug combo for Hard-to-Treat cancers shows early promise but trial halted
NCT ID NCT06560632
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested a new drug called RP-3467, alone or with olaparib, in 26 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The study was terminated, so full results are not available, but it aimed to explore a potential new option for people with few choices left.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RP-3467 (a Polθ inhibitor) and olaparib (a PARP inhibitor)
What this could lead to
If it works, this could point toward a new treatment option for advanced solid tumors that have stopped responding to other therapies.
What could go wrong
This is a very early Phase 1 trial focused on safety, not effectiveness. It was terminated, so results may be limited. Side effects from the drug combination could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
# 1001, The University of Texas M.D. Anderson Cancer Center
Houston, Texas, 77030, United States
-
# 1004, Memorial Sloan-Kettering Cancer Center
New York, New York, 10065, United States
-
# 1008, Columbia University
New York, New York, 10032, United States
-
# 1011, The Washington University
St Louis, Missouri, 63130, United States
-
# 1025, The University of California
San Francisco, California, 94158, United States